1. Ben-Ami R. Experimental Models to Study the Pathogenesis and Treatment of Mucormycosis. J Fungi (Basel). 2024;10(1):85.

https://doi.org/10.3390/jof10010085

PMid:38276032 PMCid:PMC10820959

2. Nucci M, Engelhardt M, Hamed K. Mucormycosis in South America: A review of 143 reported cases. Mycoses. 2019;62(9):730-738.

https://doi.org/10.1111/myc.12958

PMid:31192488 PMCid:PMC6852100

3. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-569.

https://doi.org/10.1128/CMR.18.3.556-569.2005

PMid:16020690 PMCid:PMC1195964

4. Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018;56(1):29-43.

https://doi.org/10.1093/mmy/myx017

PMid:28431008 

5. Gutiérrez-Delgado EM, Treviño-González JL, Montemayor-Alatorre A, Ceceñas-Falcón LA, Ruiz-Holguín E, Andrade-Vázquez CJ, et al. Chronic rhino-orbito-cerebral mucormycosis: A case report and review of the literature. Ann Med Surg (Lond). 2016;6:87-91. Published 2016 Feb 6.

https://doi.org/10.1016/j.amsu.2016.02.003

PMid:26981237 PMCid:PMC4776268

6. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421.

PMID: 31699664

7. Aksoy M, Ozcan AA, Ulas B. Prognostic factors and clinical features of rhino-orbital-mucormycosis cases: an update for patient and visual survivals. Int J Ophthalmol. 2024;17(5):916-923.

https://doi.org/10.18240/ijo.2024.05.17

PMid:38766351 PMCid:PMC11074210

8. Khalid R, Khanum I, Habib K, Ali AS, Farooqi J, Iqbal N, et al. Clinical characteristics, outcome, and factors associated with mortality of pulmonary mucormycosis: a retrospective single-center study from Pakistan. Ther Adv Infect Dis. 2024;11:20499361241251744.

https://doi.org/10.1177/20499361241251744

PMid:38716078 PMCid:PMC11075588

9. Afhami S, Adibimehr A, Mousavi SA, Vaezi M, Montazeri M, Salehi M, et al. Rate, Risk Factors, and Outcomes of Invasive Fungal Infections in Patients with Hematologic Malignancies. Int J Hematol Oncol Stem Cell Res. 2024;18(1):75-82.

https://doi.org/10.18502/ijhoscr.v18i1.14746

PMid:38680718 PMCid:PMC11055423

10. Thanjavur Sethuraman K, Athimanjeri Thiruvengadam J, Ravichandran A, Thoppappatty Sengottaiyan S. Prevalence, predictors, and outcome of pulmonary mucormycosis in COVID-19 associated rhino orbital mucormycosis in a tertiary care center in South India. Curr Med Mycol. 2023;9(3):33-37.

PMID: 38361963

11. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653.

https://doi.org/10.1086/432579

PMid:16080086 

12. Nair KS, Alagesan M, Jose D, Yoganathan C, Saravanan R, Karthikeyan K, et al. Clinical Profile and Factors Associated with Adverse Outcomes in Coronavirus Disease 2019-associated Mucormycosis: A Single-centre Study. touchREV Endocrinol. 2023;19(2):73-79.

https://doi.org/10.17925/EE.2023.19.2.2

PMid:38187078 PMCid:PMC10769467

13. Allaw F, Zakhour J, Nahhal SB, Koussa K, Bitar ER, Ghanem A, et al. Mucormycosis: A 14-Year Retrospective Study from a Tertiary Care Center in Lebanon. J Fungi (Basel). 2023;9(8):824. Published 2023 Aug 3.

https://doi.org/10.3390/jof9080824

PMid:37623595 PMCid:PMC10456049

14. Rajabi MT, Aghajani A, Rafizadeh SM, Jamshidian Tehrani M, Poursayed Lazarjani SZ, Keshmirshekan MM, et al. COVID-19 associated rhino-orbito-cerebral mucormycosis, risk factors and outcome predictors; a multicentric study. Int Ophthalmol. 2023;43(4):1375-1386.

https://doi.org/10.1007/s10792-022-02536-7

PMid:36209307 PMCid:PMC9547750

15. Bhansali A, Bhadada S, Sharma A, Suresh V, Gupta A, Singh P, et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J. 2004;80(949):670-674.

https://doi.org/10.1136/pgmj.2003.016030

PMid:15537854 PMCid:PMC1743145

16. Gür H, İsmi O, Vayısoğlu Y, Görür K, Arpacı RB, Horasan EŞ, et al. Clinical and surgical factors affecting the prognosis and survival rates in patients with mucormycosis. Eur Arch Otorhinolaryngol. 2022;279(3):1363-1369.

https://doi.org/10.1007/s00405-021-06910-6

PMid:34075487 

17. Poswal L, Bunkar GL, Sharma R, Jain A, Samar N, Mathur N, et al. A Cross-Sectional Study of First Hundred Cases of Rhino-Orbital-Cerebral Mucormycosis Admitted at a Tertiary Care Hospital. Indian J Community Med. 2022;47(3):433-436.

https://doi.org/10.4103/ijcm.ijcm_948_21

PMid:36438531 PMCid:PMC9693943

18. Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012;50(6):611-618.

https://doi.org/10.3109/13693786.2012.669502

PMid:22435877 PMCid:PMC3951871

19. Mojtahedi SS, Zarrinfar H, Bakhshaee M. Hematological Indices in COVID-19 Patients with Rhinosinusitis Mucormycosis. Iran J Otorhinolaryngol. 2024;36(2):399-405.

PMID: 38476561

20. Cho HJ, Jang MS, Hong SD, Chung SK, Kim HY, Dhong HJ. Prognostic factors for survival in patients with acute invasive fungal rhinosinusitis. Am J Rhinol Allergy. 2015;29(1):48-53.

https://doi.org/10.2500/ajra.2015.29.4115

PMid:25590320